echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: What is the success rate of discontinuation of glucocorticoids after initial therapy in RA patients?

    ARD: What is the success rate of discontinuation of glucocorticoids after initial therapy in RA patients?

    • Last Update: 2022-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    OBJECTIVE : Clinical trials have repeatedly shown that the addition of glucocorticoids (GCs) to the initial treatment of conventional synthetic (cs) DMARDs is more effective than csDMARDs alone in newly diagnosed rheumatoid arthritis (RA) patient.


    Objectives Objective : Clinical trials have repeatedly shown that in newly diagnosed patients, csDMARD alone is more effective in the initial treatment of conventional synthetic (cs) DMARD.


    Methods : A systematic literature search was performed to identify observational cohorts and clinical trials of RA patients receiving initial GC bridging therapy (defined as discontinuation of GC therapy within 1 year.


    Methods A systematic literature search was performed to identify observational cohorts and clinical trials of RA patients receiving initial GC bridging therapy (defined as discontinuation of GC therapy within 1 year.


    RESULTS : A scoping literature search for observational cohort studies found no studies that answered the research questi.


    Conclusions The success rate of post-bridging GC termination as part of the initial treatment of RA has been described in a limited number of studie.


    van Ouwerkerk L, Palmowski A, Nevins IS , et a.
    Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthrit.
    Annals of the Rheumatic Diseases2022;81 : 937-94 , et al Annals of the Rheumatic Diseases: Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.